

Table S1 Clinicopathological characteristics between MAC and AC after propensity matching analysis

Characteristics	MAC, n=460	AC, n=460	P
Sex			0.067
Male	408 (88.70)	388 (84.35)	
Female	52 (11.30)	72 (15.65)	
Age, years			0.64
<65	205 (44.57)	213 (46.30)	
≥65	255 (55.43)	247 (53.70)	
Marital			0.19
Married	304 (66.09)	299 (65.00)	
Unmarried	139 (30.22)	132 (28.70)	
Unknown	17 (3.70)	29 (6.30)	
Race			0.61
White	447 (97.17)	446 (96.96)	
Black	8 (1.74)	11 (2.39)	
Other	5 (1.09)	3 (0.65)	
Grade			0.85
I-II	154 (33.48)	146 (31.74)	
III-IV	211 (45.87)	218 (47.39)	
Unknown	95 (20.65)	96 (20.87)	
Site			0.42
Upper third	2 (0.43)	2 (0.43)	
Middle third	27 (5.87)	36 (7.83)	
Lower third	386 (83.91)	365 (79.35)	
Overlapping	11 (2.39)	18 (3.91)	
Esophagus NOS	34 (7.39)	39 (8.48)	
T			0.39
T1-2	157 (34.13)	142 (30.87)	
T3-4	222 (48.26)	223 (48.48)	
Unknown	81 (17.61)	95 (20.65)	
N			0.38
N0	179 (38.91)	163 (35.43)	
N1	224 (48.70)	228 (49.57)	
Unknown	57 (12.39)	69 (15.00)	
M			0.65
M0	293 (63.70)	280 (60.87)	
M1	142 (30.87)	155 (33.70)	
Unknown	25 (5.43)	25 (5.43)	
AJCC			0.41
I-II	143 (31.09)	125 (27.17)	
III-IV	274 (59.57)	287 (62.39)	
Unknown	43 (9.35)	48 (10.43)	
Surgery			0.89
No	283 (61.52)	286 (62.17)	
Yes	177 (38.48)	174 (37.83)	
Radiation			0.89
No	183 (39.78)	180 (39.13)	
Yes	277 (60.22)	280 (60.87)	
Chemotherapy			0.39
No	144 (31.30)	131 (28.48)	
Yes	316 (68.70)	329 (71.52)	

AC, adenocarcinoma; MAC, mucinous adenocarcinoma; SRC, signet-ring cell carcinoma; AJCC, American Joint Committee on Cancer.

Table S2 Clinicopathological characteristics between MAC and SRC after propensity matching analysis

Characteristics	MAC, n=280	SRC, n=280	P
Sex			0.59
Male	246 (87.86)	251 (89.64)	
Female	34 (12.14)	29 (10.36)	
Age, years			0.35
<65	113 (40.36)	125 (44.64)	
≥65	167 (59.64)	155 (55.36)	
Marital			0.59
Married	187 (66.79)	179 (63.93)	
Unmarried	85 (30.36)	89 (31.79)	
Unknown	8 (2.86)	12 (4.29)	
Race			0.95
White	270 (96.43)	269 (96.07)	
Black	6 (2.14)	6 (2.14)	
Other	4 (1.43)	5 (1.79)	
Grade			0.76
I-II	21 (7.50)	22 (7.86)	
III-IV	198 (70.71)	204 (72.86)	
Unknown	61 (21.79)	54 (19.29)	
Site			0.75
Upper third	2 (0.71)	2 (0.71)	
Middle third	16 (5.71)	23 (8.21)	
Lower third	237 (84.64)	226 (80.71)	
Overlapping	6 (2.14)	8 (2.86)	
Esophagus NOS	19 (6.79)	21 (7.50)	
T			0.72
T1-2	81 (28.93)	78 (27.86)	
T3-4	157 (56.07)	153 (54.64)	
Unknown	42 (15.00)	49 (17.50)	
N			0.74
N0	108 (38.57)	114 (40.71)	
N1	144 (51.43)	135 (48.21)	
Unknown	28 (10.00)	31 (11.07)	
M			0.81
M0	186 (66.43)	180 (64.29)	
M1	78 (27.86)	85 (30.36)	
Unknown	16 (5.71)	15 (5.36)	
AJCC			0.73
I-II	83 (29.64)	77 (27.50)	
III-IV	168 (60.00)	177 (63.21)	
Unknown	29 (10.36)	26 (9.29)	
Surgery			0.73
No	176 (62.86)	181 (64.64)	
Yes	104 (37.14)	99 (35.36)	
Radiation			0.23
No	103 (36.79)	118 (42.14)	
Yes	177 (63.21)	162 (57.86)	
Chemotherapy			0.46
No	77 (27.50)	86 (30.71)	
Yes	203 (72.50)	194 (69.29)	

AC, adenocarcinoma; MAC, mucinous adenocarcinoma; SRC, signet-ring cell carcinoma; AJCC, American Joint Committee on Cancer.